Citius Oncology Files 10-K/A Amendment
Ticker: CTOR · Form: 10-K/A · Filed: Jan 27, 2025 · CIK: 1851484
Sentiment: neutral
Topics: amendment, annual-report, pharmaceutical
TL;DR
CITIUS ONCOLOGY just filed an amended 10-K for FY24. Check for updates.
AI Summary
CITIUS ONCOLOGY, INC. filed an amendment (10-K/A) to its annual report for the fiscal year ended September 30, 2024. The filing, dated January 27, 2025, provides updated information regarding the company's operations and financial status. Citius Oncology, formerly TenX Keane Acquisition, is incorporated in Delaware and operates in the pharmaceutical preparations sector.
Why It Matters
This amendment provides updated disclosures for Citius Oncology's 2024 fiscal year, which is crucial for investors to assess the company's current financial health and strategic direction.
Risk Assessment
Risk Level: medium — As a 10-K/A filing, it indicates a correction or addition to a previous filing, suggesting potential issues or a need for clarification that could impact investor understanding.
Key Numbers
- 0930 — Fiscal Year End (Indicates the end of the reporting period for the annual report.)
Key Players & Entities
- CITIUS ONCOLOGY, INC. (company) — Registrant
- September 30, 2024 (date) — Fiscal Year End
- January 27, 2025 (date) — Filing Date
- TenX Keane Acquisition (company) — Former Company Name
- 001-41534 (other) — SEC File Number
FAQ
What specific information was amended in this 10-K/A filing?
The filing is an amendment to the annual report for the fiscal year ended September 30, 2024, indicating that previously filed information has been updated or corrected.
When was the original 10-K filed, and what is the purpose of this amendment?
The filing date for this amendment is January 27, 2025. The purpose is to amend the annual report filed for the fiscal year ended September 30, 2024.
What is Citius Oncology's former company name?
Citius Oncology, Inc. was formerly known as TenX Keane Acquisition, with a date of name change on March 15, 2021.
Where is Citius Oncology, Inc. headquartered?
The company's principal executive offices are located at 11 Commerce Drive, First Floor, Cranford, NJ 07016.
What is Citius Oncology's SIC code?
Citius Oncology, Inc. has a Standard Industrial Classification (SIC) code of 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,619 words · 18 min read · ~15 pages · Grade level 10.8 · Accepted 2025-01-27 16:30:08
Key Financial Figures
- $0.0001 — ich Registered Common Stock, par value $0.0001 per share CTOR The NASDAQ Capital Marke
Filing Documents
- ea0228749-10ka1_citius.htm (10-K/A) — 233KB
- ea022874901ex31-3_citius.htm (EX-31.3) — 3KB
- ea022874901ex31-4_citius.htm (EX-31.4) — 4KB
- 0001213900-25-007012.txt ( ) — 467KB
- tenk-20240930.xsd (EX-101.SCH) — 3KB
- tenk-20240930_lab.xml (EX-101.LAB) — 33KB
- tenk-20240930_pre.xml (EX-101.PRE) — 17KB
- ea0228749-10ka1_citius_htm.xml (XML) — 7KB
Signatures
Signatures 16 i PART III
Directors, Executive Officers and
Item 10. Directors, Executive Officers and Corporate Governance The Company was originally formed as "TenX Keane Acquisition Corp." on March 21, 2021, as a Cayman Islands exempted company for the purpose of entering into a business combination with one or more businesses or entities. Effective August 5, 2024, the Company reincorporated as a Delaware corporation and changed its name to "Citius Oncology, Inc." On August 12, 2024, the Company completed the acquisition of its subsidiary, Citius Oncology Sub, Inc. Prior thereto, Citius Oncology Sub, Inc. was a subsidiary of Citius Pharma. Prior to August 12, 2024, the Company conducted no operations. Citius Oncology Sub, Inc. began operations on April 1, 2022. The following sets forth information concerning our directors and executive officers as of December 31, 2024: Name Age Title Leonard Mazur 79 Chairman and Chief Executive Officer Myron Holubiak 77 Secretary and Director Suren Dutia 82 Director Dr. Eugene Holuka 65 Director Dennis M. McGrath 67 Director Robert Smith 64 Director Joel Mayersohn 66 Director Carol Webb 78 Director Jaime Bartushak 57 Chief Financial Officer and Treasurer Myron S. Czuczman 65 Chief Medical Officer Leonard Mazur Leonard Mazur is the Chairman and Chief Executive Officer of the Company, a position he has held since August 12, 2024. Prior thereto, he served as the Chief Executive Officer of Citius Oncology Sub, Inc., beginning on April 1, 2022. Mr. Mazur also serves as the Executive Chairman and Secretary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR) and has been a member of the board of directors of Citius Pharma since September 2014. In May 2022, Mr. Mazur became the Chief Executive Officer of Citius Pharma. He also serves as the Secretary of Citius Pharma's majority-owned subsidiary, NoveCite, Inc. ("NoveCite"), and provides other guidance to Citius Pharma and NoveCite. Since August 2021, Mr. Mazur has served on the boa